Breaking News

Cobra Biologics Appoints CSO

May 7, 2014

Smith to develop scientific excellence and enhance R&D platforms

Dr. Daniel C. Smith has been appointed chief scientific officer at Cobra Biologics, with responsibility for developing scientific excellence across the group and enhancing Cobra’s DNA, virus, microbial and mammalian proteins R&D platforms.
 
Dr. Smith joins the company from HealthTech & Medicines Knowledge Transfer Network (KTN), where he served as a Knowledge Transfer Manager on the bioProcessUK team, responsible for driving the innovation agenda for biologics bioprocessing in the UK. Previously, Dr. Smith held a variety of roles progressing from senior scientist to commercial scientific development manager, responsible for developing the strategy for customer’s projects, and maintaining scientific oversight of Cobra’s R&D projects.
 
Peter Coleman, chief executive officer at Cobra Biologics, said, “This is a significant appointment for Cobra and I am personally very pleased that Dan has decided to return to Cobra as our new CSO. He has a tremendous enthusiasm for science and its application in our industry and from working with him previously, I firmly believe he has experience and ability to further establish Cobra as a leading scientific organization.”
blog comments powered by Disqus
  • CMO Systems

    CMO Systems

    Philip K. Burns, CRO Consulting||April 5, 2016
    A CMO system includes four aspects of the product lifecycle: regulatory, technical, compliance, and operations.

  • Injectables: The New Oral?

    Injectables: The New Oral?

    Tugrul Kararli, Kurt Sedo, Josef Bossart, PharmaCircle LLC||April 5, 2016
    The growth trend of injectables continues across the pharma landscape.

  • Biopharmaceutical Contract Manufacturing Contract Negotiations

    Biopharmaceutical Contract Manufacturing Contract Negotiations

    William Downey, HighTech Business Decisions||April 5, 2016
    Navigating the complexities of supply agreements.